



IFW

Docket No.: 0480-0165PUS1
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Richard BÉLIVEAU et al.

Application No.: 10/556,145

Confirmation No.: 5957

Filed: August 21, 2006

Art Unit: N/A

For: COMPOUND AND METHOD FOR
REGULATING PLASMINOGEN
ACTIVATION AND CELL MIGRATION

Examiner: Not Yet Assigned

INFORMATION DISCLOSURE STATEMENT
(SUBMISSION AFTER FILING OF AN APPLICATION BUT BEFORE FINAL
REJECTION OR NOTICE OF ALLOWANCE OR CONCURRENTLY WITH A RULE
1.114 RCE APPLICATION)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Pursuant to 37 C.F.R. §§ 1.97 and 1.98, applicant(s) hereby submit(s) an Information Disclosure Statement for consideration by the Examiner.

I. LIST OF PATENTS, PUBLICATIONS OR OTHER INFORMATION

The patents, publications, or other information submitted for consideration by the Office are listed on the PTO-SB08(s), attached hereto.

II. COPIES

- ☒ a. Copies of cited U.S. patents and patent application publications are not included.
Copies of foreign patent documents and non-patent literature are included.

☐ b. Some or all of the documents listed on the PTO-SB08 are not enclosed because they were cited in the International Search Report and copies should already be in the PTO file. If copies are needed, please contact the undersigned.

☐ c. REFERENCES PREVIOUSLY CITED OR SUBMITTED - Pursuant to 37 C.F.R. §1.98(d), consideration of information listed on the PTO-SB08 form(s) is requested since any patents, publications, or other information which are listed on the PTO-SB08 form(s) but for which copies are not enclosed herewith, were previously cited by or submitted to the PTO in one of the following applications which has been relied upon for an earlier filing date under 35 U.S.C. § 120:

U.S. Appl. No(s) and U.S. Filing Date

PCT/CA2004/000697 filed May 7, 2004

III. CONCISE EXPLANATION OF THE RELEVANCE

(check at least one box)

☒ a. DOCUMENTS IN THE ENGLISH LANGUAGE - The patents, publications, or other information listed on the attached PTO SB08 are in the English language and therefore, do not require a statement of relevancy.

☐ b. DOCUMENTS NOT IN THE ENGLISH LANGUAGE - A concise explanation of the relevance of all patents, publications, or other information listed that is not in the English language is as follows:

☐ c. ENGLISH LANGUAGE SEARCH REPORT - An English language version of the search report or action that indicates the degree of relevance found by the foreign office is attached, thereby satisfying the requirement for a concise explanation. See MPEP 609(III)(A)(3).

☐ d. OTHER - The following additional information is provided for the Examiner's consideration.

IV. FEES (check one box)

☐ a. This Information Disclosure Statement is being filed concurrently with the filing of a new patent application; therefore, no fee is required.

☐ b. This Information Disclosure Statement is being filed concurrent with the filing of a continuation-in-part, continuation, or divisional patent application; therefore, no fee is required.

☐ c. This Information Disclosure Statement is being filed within three months of the filing date of a national application (37 C.F.R. § 1.97(b)(1)). No fee or statement is required.
(This section is not to be used with RCE's.)

☐ d. This Information Disclosure Statement is being filed within three months of the date of entry of the national stage as set forth in § 1.491 in an international application (37 C.F.R. § 1.97(b)(2)). No fee or statement is required.

☐ e. This Information Disclosure Statement is being filed concurrently with the filing of a Request for Continued Examination under § 1.114 (37 C.F.R. § 1.97(b)(4)). No fee or statement is required.

☒ f. This Information Disclosure Statement is being filed before the mailing date of a first Action on the merits (37 C.F.R. § 1.97(b)(3)). No fee or statement is required. In the event that a first Office Action on the merits has been issued, please consider this IDS under 37 C.F.R. § 1.97(c) and see the statement under 37 C.F.R. § 1.97(e) below, or, if no statement has been made, charge our deposit account for the fee as required by 37 C.F.R. § 1.17(p).

☐ g. This Information Disclosure Statement is being filed before the mailing date of a Final Office Action under 37 C.F.R. § 1.113 (See 37 C.F.R. § 1.97(c)(1)) or before the mailing date of a Notice of Allowance under 37 C.F.R. § 1.311 (See 37 C.F.R. § 1.97(c)(2)).

☐ No statement; therefore, a fee as required by 37 C.F.R. § 1.17(p) is attached.

or

☐ See the statement below. No fee is required.

V. STATEMENT UNDER 37 C.F.R. § 1.97(e)

(check only one box)

The undersigned hereby states that:

☐ a. **Each item of information contained in the IDS was first cited in any communication from a foreign Patent Office in a counterpart foreign application not more than 30 days prior to the filing of this IDS; or**

☐ b. Each item of information contained in the IDS was first cited in any communication from a foreign Patent Office in a counterpart foreign application not more than three months prior to the filing of this IDS; or

☐ c. No item of information contained in the IDS was cited in a communication from a foreign Patent Office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of IDS was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of the IDS.

☐ d. Some of the items of information were cited in a communication from a foreign Patent Office. As to this information, the undersigned states that each item of information contained in the IDS was first cited in a communication from a foreign Patent Office in a counterpart foreign application not more than three months prior to the filing of this IDS. As to the remaining information, the undersigned hereby states that no item of this remaining information contained in the IDS was cited in a communication from a foreign Patent Office in a counterpart foreign application and, to the best of my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this statement.

VI. PAYMENT OF FEES (check one box)


- ☐ The required fee is listed on the attached Fee Transmittal.
- ☒ No fee is required.

If the Examiner has any questions concerning this IDS, he/she is requested to contact the undersigned. If it is determined that this IDS has been filed under the wrong rule, the PTO is requested to consider this IDS under the proper rule and charge the appropriate fee to Deposit Account No. 02-2448.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to our Deposit Account No. 02-2448 for any additional fees required under 37 C.F.R. § 1.16 or under § 1.17; particularly, extension of time fees.


Dated: May 3, 2007

Respectfully submitted,

f By  #42874.
Mark J. Nuell
Registration No.: 36,623
BIRCH, STEWART, KOLASCH & BIRCH, LLP
8110 Gatehouse Road
Suite 100 East
P.O. Box 747
Falls Church, Virginia 22040-0747
(703) 205-8000
Attorney for Applicant

Attachment(s):

- ☒ PTO/SB/08
☒ Document(s)
☐ Foreign Search Report(s)
☐ Fee
☐ Other:



Used in Lieu of PTO/SB/08A/B
(Based on PTO 04-07 version)

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Complete if Known		
			Application Number	10/556,145-Conf. #5957	
			Filing Date	August 21, 2006	
			First Named Inventor	Richard BÉLIVEAU	
			Art Unit	N/A	
			Examiner Name	Not Yet Assigned	
			Attorney Docket Number	0480-0165PUS1	
Sheet	1	of	1		

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	CA	Aleman et al., 1993, J Cell Sci, 104:1155-1162.	
	CB	Andreasen et al., 1997, Int. J Cancer, 72:1-22.	
	CC	Baker et al., 1992, FEBS Letters, 298(2,3):215-218.	
	CD	Bass et al., 2002, J Biol Chem, 277(49):46845-46848.	
	CE	Brown et al., 1981, Proc Natl Acad Sci USA, 78(1):539-543.	
	CF	Brown et al., 1982, Nature, 296:171-173	
	CG	Bu et al., 1996, J Biol Chem, 271(36):22218-22224	
	CH	Conese et al., 1995, J Cell Biol, 131(6):1609-1622	
	CI	Conellis et al., 1989, Proc Natl Acad Sci USA, 86:4828-4832	
	CJ	Dano et al., 1985, Adv Cancer Res, 44:139-266	
	CK	Dehouck et al., 1992, J Neurochem, 58 (5):1790-1797	
	CL	Demeule, et al., 2002 J Neurochem 83:924-933	
	CM	Fillebeen et al., 1999 J Biol Chem 274(11):7011-7017	
	CN	Food et al., 1994 J Biol Chem. 269(4):3034-3040	
	CO	Gong et al., 2001 J Biol Chem 276(22):19078-19083	
	CP	Herz et al., 2001J Clin Invest 108(6):779-784	
	CQ	Jefferies et al., 1996 Brain Res 712:122-126	
	CR	Johnsson et al., 1991 Anal Biochem 198:268-277	
	CS	Kennard et al., 1996 Nat Med 2:1230-1235	
	CT	Kozyraki et al., 2001 Proc Natl Acad Sci USA 98(22):12491-12496	
	CU	Li et al., 2002 J Biol Chem 277(44):42366-42371	
	CV	Liu et al., 2002 J. Biol Chem 276(31):28889-28896	
	CW	Min et al., 1996 Cancer Res 56:2428-2433	
	CX	Neels et al., 1999 J Biol Chem 274(44):31305-31311	
	CY	Nielsen et al., 1988 J. Biol Chem 263(5):2358-2363	
	CZ	Nykjaer et al., 1997 EMBO J 16(10):2610-2620	
	CA1	Olson et al., 1992 J Biol Chem 267(13):9129-9133	
	CB1	Ploug et al., 1991 J Biol Chem 266(3):1926-1933	
	CC1	Reijerkerk et al., 2000 Eur J Cancer, 36:1695-1705	
	CD1	Richardson, 2000 Eur J. Biochem 267:1290-1298	
	CE1	Sekyere et al., 2000 FEBS Letters 483:11-16	
	CF1	Stahl et al., 1997 Int J Cancer 71:116-122	
	CG1	Tarui et al., 2002 J Biol Chem 277(37):33564-33570	
	CH1	Weaver et al., 1997 J Biol Chem 272(22):14372-14379	
	CI1	Woodbury et al., 1980 Proc Natl Acad Sci USA 77(4):2183-2187	
	CJ1	Woodbury et al., 1981, Int J Cancer, 27:145-149	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
--------------------	--	-----------------	--